LXO Group announces the acquisition of prescription drug Nimotop® from Bayer

Press Release, november 06th, 2023 - Laboratoire X.O ("LXO"), is pleased to announce the acquisition of prescription drug Nimodipine under the brand name Nimotop® from Bayer, for several markets across different regions excluding Mainland China.

6 Nov 2023

Laboratoire XO is moving!

To support its growth, Laboratoire XO is moving to new premises and reaching for the sky!

10 Jul 2023

Laboratoire XO moves into a new phase of its growth with the support of Stanley Capital

Press Release, october 04th, 2022 - Stanley Capital Partners (SCP) has acquired a majority stake in French pharmaceutical group Laboratoire XO (Lab XO). Debt was provided by US giant Ares Management.

4 Oct 2022

Let’s celebrate 5 years of Laboratoire XO!

Laboratoire X.O is a French success story.

30 Apr 2020